March 6, 2020 / 12:28 PM / a month ago

BRIEF-Milestone Pharmaceuticals Reports Qtrly Loss Per Share Of $0.75

March 6 (Reuters) - Milestone Pharmaceuticals Inc:

* MILESTONE PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATE

* MILESTONE PHARMACEUTICALS - TOPLINE DATA FROM PHASE 3 NODE-301 TRIAL OF ETRIPAMIL IN PATIENTS WITH PSVT EXPECTED IN MARCH

* MILESTONE PHARMACEUTICALS - AS OF DEC. 31, 2019, HAD CASH, CASH EQUIVALENTS OF $119.8 MILLION VERSUS $86.0 MILLION AS OF DEC. 31, 2018

* MILESTONE PHARMACEUTICALS - QTRLY LOSS PER SHARE $0.75

* Q4 EARNINGS PER SHARE VIEW $-0.52 — REFINITIV IBES DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below